Blueprint Medicines Corp (NAS:BPMC)
$ 102.81 0.42 (0.41%) Market Cap: 6.44 Bil Enterprise Value: 6.09 Bil PE Ratio: 0 PB Ratio: 20.73 GF Score: 72/100

Blueprint Medicines Corp at Goldman Sachs Global Healthcare Conference Transcript

Jun 12, 2019 / 10:20PM GMT
Release Date Price: $86.19 (+1.11%)
Salveen Jaswal Richter
Goldman Sachs Group Inc., Research Division - VP

Good afternoon, everyone. Thanks for joining us. I'm Salveen Richter, one of the biotechnology analysts at Goldman Sachs and we're pleased to have the Blueprint team with us. With us here on stage, we have Jeff Albers, CEO and President.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group Inc., Research Division - VP

Jeff, maybe to start, earlier this year, you announced the 2020 Blueprint. Can you just update us on your progress towards the goals there and what we should expect for the rest of the year?

Jeffrey W. Albers
Blueprint Medicines Corporation - CEO, President & Director

Sure. So first off, on behalf of all the Blueprint employees, thanks for including us at the conference. At a high level, I think the Blueprint 2020 embodies what we're trying to execute from a corporate vision perspective, and there's really 3 fundamental components of that one: the first is to leverage our kinase library, our chemical

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot